AUPH shorts retreat to a one-year low as options skew spikes and TD Cowen lifts its target

AUPH short interest has just hit its lowest level in over a year, yet options traders are suddenly the most defensive they have been in months, a divergence that frames the whole setup heading into a November 5 earnings date.

Short interest in Aurinia Pharmaceuticals has fallen to 5.9% of the free float, down 12% over the past month and down roughly a third from where it stood in early September. The pace of that retreat is notable: bears held more than 9.3 million shares short as recently as early September; that figure is now below 7.8 million. Borrow conditions confirm the exit. Cost to borrow has dropped 33% over the past month to just 0.34%, and availability at 1,688% of current short interest means the lending pool is nowhere near stretched. There is no mechanical squeeze pressure, no scarcity of supply, and no sign that remaining shorts are trapped.

The options market is telling a different story. The put/call ratio jumped to 0.73 this week from a 20-day average of 0.57, a move 2.5 standard deviations above the mean and the most defensive reading since last September's elevated patch. That cluster of put-buying arrived just as the stock is trading at $16.74, only 2% off its 52-week highs, and two weeks before a quarterly print. Whether the protective positioning reflects concern about the earnings outcome or simply routine hedging into a binary event, the contrast with the short-covering trend is real: borrowed conviction is leaving the stock even as hedged conviction is entering via puts.

The analyst read this week is modestly constructive. TD Cowen lifted its price target on AUPH to $18 from $17 this morning while keeping its Buy rating, the most recent and most relevant move given its timing, two weeks from earnings. The Street's mean target sits at $18, implying about 7.5% upside from current levels. RBC Capital remains at Sector Perform with a $16 target, essentially flat to the current price, reflecting the ceiling some analysts put on near-term upside given market penetration headwinds for LUPKYNIS. The bear case centres on those commercial challenges: modest patient uptake in a competitive autoimmune market, and heavy clinical spending on the pipeline candidate AUR200. Bulls counter with a revenue trajectory projected to reach $932 million by 2033 from roughly $244 million last year. ORTEX factor scores are mixed: EPS surprise ranks in the 72nd percentile, a decent beat record, while the short score rank at 39 and dividend score at 32 add little directional signal.

The activist register adds a layer of complexity that distinguishes AUPH from most mid-cap biotech names. Tang Capital Management, whose CEO Kevin Tang also runs Aurinia, holds 10% of the company on a Schedule 13D, a filing that flags activist intent. Tang raised that stake from 9.2% to 10% as recently as June 4, and the open-market purchases in late May and early June totalled more than $12 million at prices around $15.28 to $15.35. A second 13D filer, Chin Kyu Huh, last reported 4.4% of the class in August, down from 5%, and may have exited the 5% threshold without a subsequent filing, as the disclosure rules permit. Stakes on the 13D register are as last disclosed, and holders dropping below the 5% level can exit without further notice. The institutional register also shows Goldman Sachs Asset Management adding more than 4 million shares in the quarter to October 1, a position now at 3.7% of shares outstanding. BlackRock added 348,000 shares in the same period to reach 6.2%.

On the peer comparison, AUPH's 2.3% gain over the past week looks restrained. Correlated Nasdaq biotech names including SYRE, NVCT, and ARQT put up weekly moves of 14%, 13%, and 26% respectively. PRQR was the one laggard, down 6.8% on the week. The median weekly move across the closest correlated peers was 7.7%, so AUPH's modest gain came despite, not alongside, a broader bid for the group.

Recent earnings prints offer a mixed baseline. The last four quarterly results produced day-one moves of minus 4.2%, plus 4.3%, plus 6.4%, and plus 2.0%, with the five-day drift fading after most of those reactions. The November 5 date is the concrete thing to watch next, particularly whether the option put-buying ahead of it proves well-placed or simply reflects standard pre-earnings hedging that unwinds into the release.